Tammi Gaskins was named Chief Executive Officer of Ironwood Pharmaceuticals Inc, succeeding Thomas McCourt, effective January 1, 2027. As of November 6, 2026, Ironwood Pharmaceuticals Inc has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from May 13, 2026 to October 16, 2026, naming 2 appointments and 2 departures (Form 8-K, October 16, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Ironwood Pharmaceuticals Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Ironwood Pharmaceuticals Inc reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-05-13 to 2026-10-16. They name 3 people, with 2 appointments and 2 departures. Every row below is cited to the filing it comes from, and this page adds each new change as Ironwood Pharmaceuticals Inc files it.
Also on the record for Ironwood Pharmaceuticals Inc
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 28, 2026 | Stake report, Schedule 13G/A, by BANK OF AMERICA CORP /DE/ | 3.2% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 8.43% of the class | 5%+ stakes | Source |
| August 7, 2026 | Stake report, Schedule 13G, by STATE STREET CORPORATION | 5.4% of the class | 5%+ stakes | Source |
| July 28, 2026 | Stake report, Schedule 13G/A, by BlackRock, Inc. | 8.1% of the class | 5%+ stakes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 9.22% of the class | 5%+ stakes | Source |
| May 14, 2026 | Stake report, Schedule 13G/A, by Renaissance Technologies LLC | 4.9% of the class | 5%+ stakes | Source |
| April 27, 2026 | Stake report, Schedule 13G/A, by BANK OF AMERICA CORP /DE/ | 6.1% of the class | 5%+ stakes | Source |
| March 27, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | — | 5%+ stakes | Source |
| March 19, 2026 | Stake report, Schedule 13D/A, by Sarissa Capital Management LP | 5.8% of the class | 5%+ stakes | Source |
| February 17, 2026 | Stake report, Schedule 13G/A, by Armistice Capital, LLC | 9.85% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G, by BANK OF AMERICA CORP /DE/ | 7.4% of the class | 5%+ stakes | Source |
| November 12, 2025 | Stake report, Schedule 13G/A, by Barclays PLC | 1.95% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Ironwood Pharmaceuticals Inc now and the warning signs.
Free to see. No signup.
Keep reading
More on Ironwood Pharmaceuticals Inc and the records around it.
Ironwood Pharmaceuticals Inc elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- Renaissance Technologies LLC also filed stake reports on 46 other companies: AMERICAN PUBLIC EDUCATION INC (Aug 2026), Bolt Biotherapeutics, Inc. (Aug 2026), Commercial Vehicle Group, Inc. (Aug 2026)
- BANK OF AMERICA CORP /DE/ also filed stake reports on 74 other companies: BlackRock 2037 Municipal Target Term Trust (Nov 2026), TRIMAS CORP (Nov 2026), PIMCO CALIFORNIA MUNICIPAL INCOME FUND (Nov 2026)
- Barclays PLC also filed stake reports on 116 other companies: BIGLARI HOLDINGS INC-B (Nov 2026), CABLE ONE INC (Nov 2026), CALISA ACQUISITION CORP (Nov 2026)
Watch Ironwood Pharmaceuticals Inc
Get an email when Ironwood Pharmaceuticals Inc files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Ironwood Pharmaceuticals Inc?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Ironwood Pharmaceuticals Inc: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Ironwood Pharmaceuticals Inc covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 15 records.
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-10-16 | In | Chief Executive Officer | 2027-01-01 | 8-K, 2026-10-16 | |
| 2026-10-16 | In | Director | 8-K, 2026-10-16 | ||
| 2026-10-16 | Out | Chief Executive Officer | 2026-12-31 | 8-K, 2026-10-16 | |
| 2026-05-13 | Out | Chief Financial Officer | 2026-05-15 | 8-K, 2026-05-13 |
Who leads Ironwood Pharmaceuticals Inc, as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Executive Officer: Tammi Gaskins, appointed, effective 2027-01-01 (filed 2026-10-16).
- Director: Tammi Gaskins, appointed (filed 2026-10-16).
- Chief Financial Officer: Gregory Martini, departure reported, effective 2026-05-15 (filed 2026-05-13). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Ironwood Pharmaceuticals Inc: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Executive Officer at Ironwood Pharmaceuticals Inc, with the record behind each one.
Find candidates like Chief Executive Officer at Ironwood Pharmaceuticals IncEvery change, in the filing's words
Appointed: Tammi Gaskins, Chief Executive Officer, effective 2027-01-01
Ironwood Pharmaceuticals, Inc. (the "Company") today announced that, on October 12, 2026, the Board of Directors (the "Board") appointed Tammi Gaskins, the Company's Senior Vice President, Chief Commercial Officer, as Chief Executive Officer, effective January 1, 2027 (the "Transition Date").
Appointed: Tammi Gaskins, Director
The Board increased the size of the Board from eight to nine directors and elected Ms. Gaskins as a director, in each case, effective as of the Transition Date.
Departing: Thomas McCourt, Chief Executive Officer, effective 2026-12-31
The Company also announced today that, on October 12, 2026, Thomas McCourt notified the Board of his decision to retire as Chief Executive Officer, effective December 31, 2026, following 17 years of service to the Company, including five years in that role.
- As an employee of the Company, Ms. Gaskins will not receive any additional compensation for her service on the Board.
- Mr. McCourt will continue to serve as a director on the Board following his retirement as Chief Executive Officer.
- As part of the transition, the Company and Mr. McCourt plan to enter into a consulting agreement effective as of the Transition Date, pursuant to which Mr. McCourt will serve as consultant to the Company following the Transition Date, for an anticipated consulting fee of $10,000 per month.
- In connection with her appointment as Chief Executive Officer and effective as of the Transition Date, Ms. Gaskins will receive an annual base salary of $775,000 and will have an individual bonus target of 75% of her annual base salary, subject to achievement of corporate goals.
- In addition, as of the Transition Date, Ms. Gaskins will receive a grant of restricted stock units ("RSUs") and performance-based restricted stock unit awards ("PSUs"), under the Company's Amended and Restated 2019 Equity Incentive Plan.
- The target grant value of the RSUs will be approximately $2,000,000 and the target grant value of the PSUs at target performance will be approximately $2,000,000.
- Each RSU and PSU represents a right to receive shares of the Company's Class A common stock upon vesting of such awards.
Departing: Gregory Martini, Chief Financial Officer, effective 2026-05-15
On May 8, 2026, Gregory Martini notified Ironwood Pharmaceuticals, Inc. (the "Company") that he is resigning from his position as Senior Vice President, Chief Financial Officer, effective May 15, 2026.
- Mr. Martini's resignation is not due to any disagreement with the Company on any matter relating to the Company's financial reporting.
- Effective May 15, 2026, Ronald Silver, age 44, the Company's Senior Vice President, Corporate Controller and Chief Accounting Officer, will also serve as the Company's interim chief financial officer and principal financial officer.
- Mr. Silver joined the Company in June 2018.
- Mr. Silver has served as the Company's Senior Vice President, Corporate Controller and Chief Accounting Officer since January 2025.
- Mr. Silver previously served as the Company's Corporate Controller and principal accounting officer from July 2021, Corporate Controller from April 2019 to July 2021, and Assistant Controller from June 2018 until April 2019.
- Prior to joining the Company, Mr. Silver held various accounting and financial reporting positions at Eze Software Group LLC from August 2014 to June 2018, including Director of Technical Accounting & Reporting from January 2016 to November 2016, and Director of Accounting & Assistant Controller from December 2016 to June 2018.
- Earlier in his career, Mr. Silver held various positions of increasing responsibility in the audit and consulting practices at RSM, LLP from August 2004 through August 2014.
Tools for this story
Each opens in a new tab, filled in for Ironwood Pharmaceuticals Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.